Indian pharmaceutical companies and industry experts do not see a downside for Indian drug makers following drug maker Teva's $40 billion dollar... ...http://smartinvestor.business-standard.com/market/Compnews-326392-Compnewsdet-Teva_Allergan_deal_will_not_impact_Indian_pharma_says_experts.htm
India's pharma sector has been presenting mixed growth trends. On the one hand, growing demand is presenting an opportunity, while on the other,... ...http://www.mydigitalfc.com/technical-analysis/under-weather-310
Commerce and Industry Minister Nirmala Sitharaman said the matter was examined. Photo: Bloomberg New Delhi: The Ministry of Commerce and... ...http://www.livemint.com/Politics/xr2ilPf1kJIDNzwzK07nrO/Commerce-Ministry-considering-proposal-for-CL-to-anticancer.html
MNC reviewing options on Lee Pharma's CL In a statement reacting to Lee Pharma's application for a compulsory license (CL) for saxagliptin,... ...http://www.financialexpress.com/article/pharma/market-pharma/confident-in-our-ip-astrazeneca/104895/
With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to pharmaceutical IP... ...http://www.financialexpress.com/article/pharma/editors-note/lee-pharma-revives-the-cl-debate/104383/
Erlonat (Erlotinib) is a Kinase...